224 related articles for article (PubMed ID: 19364972)
1. Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Liedtke C; Hatzis C; Symmans WF; Desmedt C; Haibe-Kains B; Valero V; Kuerer H; Hortobagyi GN; Piccart-Gebhart M; Sotiriou C; Pusztai L
J Clin Oncol; 2009 Jul; 27(19):3185-91. PubMed ID: 19364972
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Tordai A; Wang J; Andre F; Liedtke C; Yan K; Sotiriou C; Hortobagyi GN; Symmans WF; Pusztai L
Breast Cancer Res; 2008; 10(2):R37. PubMed ID: 18445275
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Peintinger F; Buzdar AU; Kuerer HM; Mejia JA; Hatzis C; Gonzalez-Angulo AM; Pusztai L; Esteva FJ; Dawood SS; Green MC; Hortobagyi GN; Symmans WF
Ann Oncol; 2008 Dec; 19(12):2020-5. PubMed ID: 18667396
[TBL] [Abstract][Full Text] [Related]
5. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
[TBL] [Abstract][Full Text] [Related]
7. High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
Wang Y; Sparano JA; Fineberg S; Stead L; Sunkara J; Horwitz SB; McDaid HM
Clin Breast Cancer; 2013 Apr; 13(2):103-8. PubMed ID: 23218766
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
12. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Zambetti M; Mansutti M; Gomez P; Lluch A; Dittrich C; Zamagni C; Ciruelos E; Pavesi L; Semiglazov V; De Benedictis E; Gaion F; Bari M; Morandi P; Valagussa P; Luca G
Breast Cancer Res Treat; 2012 Apr; 132(3):843-51. PubMed ID: 21750964
[TBL] [Abstract][Full Text] [Related]
13. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Lee JK; Coutant C; Kim YC; Qi Y; Theodorescu D; Symmans WF; Baggerly K; Rouzier R; Pusztai L
Clin Cancer Res; 2010 Jan; 16(2):711-8. PubMed ID: 20068086
[TBL] [Abstract][Full Text] [Related]
14. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M; Symmans WF; Stec J; Damokosh AI; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi GN; Pusztai L
J Clin Oncol; 2004 Jun; 22(12):2284-93. PubMed ID: 15136595
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Mazouni C; Kau SW; Frye D; Andre F; Kuerer HM; Buchholz TA; Symmans WF; Anderson K; Hess KR; Gonzalez-Angulo AM; Hortobagyi GN; Buzdar AU; Pusztai L
Ann Oncol; 2007 May; 18(5):874-80. PubMed ID: 17293601
[TBL] [Abstract][Full Text] [Related]
18. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.
Shen K; Qi Y; Song N; Tian C; Rice SD; Gabrin MJ; Brower SL; Symmans WF; O'Shaughnessy JA; Holmes FA; Asmar L; Pusztai L
BMC Med Genomics; 2012 Nov; 5():51. PubMed ID: 23158478
[TBL] [Abstract][Full Text] [Related]
19. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
